cally associated with hepatocellular carcinoma (HCC), but its role in HCC remains poorly understood due to technological limitations. In this study, we systematically characterize HBV in HCC patients. HBV sequences were enriched from 48 HCC patients using an oligo-bead-based strategy, pooled together and sequenced using the FLX-Genome-Sequencer. In the tumors, preferential integration of HBV into promoters of genes (P < 0.001) and significant enrichment of integration into chromosome 10 (P < 0.01) were observed. Integration into chromosome 10 was significantly associated with poorly differentiated tumors (P < 0.05). Notably, in the tumors, recurrent integration into the promoter of the human telomerase reverse transcriptase (TERT) gene was found to correlate with increased TERT expression. The preferred region within the HBV genome involved in integration and viral structural alteration is at the 3ʹ-end of hepatitis B virus X protein (HBx), where viral replication/transcription initiates. Upon integration, the 3ʹ-end of the HBx is often deleted. HBxhuman chimeric transcripts, the most common type of chimeric transcripts, can be expressed as chimeric proteins. Sequence variation resulting in non-conservative amino acid substitutions are commonly observed in HBV genome. This study highlights HBV as highly mutable in HCC patients with preferential regions within the host and virus genome for HBV integration/structural alterations.
Introduction
Hepatocellular carcinoma (HCC), the most frequent subtype of liver cancer, is the third leading cause of cancer death in the world (1) . HCC patients usually have poor prognosis due to high rates of postoperative recurrence and metastasis incidence (2, 3) . Hepatitis B and C virus (HBV and HCV) infection is the most epidemiologically associated risk factor for HCC accounting for 75-80% of HCC cases worldwide (4, 5) . Chronic HBV carriers have a 20-100-fold higher risk for HCC (6) (7) (8) (9) . HBV is a DNA virus with 3.2 kb circular and partially double-stranded genome containing four open reading frames (ORFs) encoding surface (S), core (C), polymerase (P) and the X protein.
A significant feature of chronic HBV infection is the integration of subgenomic HBV DNA fragments into different locations within the host DNA (10) (11) (12) (13) (14) . Tumor progression is often associated with the rearrangement and partial gain or loss of both viral and cellular sequences (15) (16) (17) . However, the role of the integrated HBV DNA in hepatocarcinogenesis remains uncertain and controversial. Various small-scale isolated studies suggested that HBV integrates randomly in the host genome (16) , or primarily into intronic or intergenic regions (18) , chromosomal fragile sites, scaffold/matrix attachment regions and repeat/satellite sequence-rich region of the host genome (10) .
Integration of HBV into host genome can have two potential consequences: (i) the host genome becomes altered ('cis' effect) and (ii) the HBV genome becomes altered ('trans' effect). The 'cis' effect of HBV integration includes insertional mutagenesis, which can potentially disrupt host gene function or alter the regulation of host genes [e.g. telomerase reverse transcriptase (TERT)] (19) .
The integrated HBV genome was also found to be altered in several ways including having portions of the HBV genome being deleted, inverse duplicated or rearranged (10) . Despite drastic rearrangements, the coding regions of PreS2 and hepatitis B virus X protein (HBx) were reported to be generally conserved and can be transcribed (20) . Hence, these two HBV proteins have been implicated to play a 'trans' role in hepatocarcinogenesis (21) (22) (23) (24) (25) (26) (27) .
Because HBV integration can disrupt host genes/deregulate host gene expression or a subset of rearranged integrants may play an important role in hepatocarcinogenesis, it is worthwhile to systematically characterize HBV in a large number of HCC patients.
Technological limitations of PCR and southern blot-based methods (28) (29) (30) (31) (32) (33) (34) (35) restricted previous studies to characterize only the most common HBV integrant(s) in only a few patients. As HBV is highly mutated at both nucleotide and structural levels, the lack of a priori knowledge on the HBV sequences in each patient sample may lead to PCR failure and false-negative results with PCR-based methods when the designed primers reside on deleted or polymorphic sites of HBV genome. Recently, two studies reported 'short-read' whole genome paired-end deep sequencing of 4 and 88 HCC patients, respectively (36, 37) . Due to limitations of short reads generated using these platforms, integration sites were only inferred from paired-end reads containing both human and virus sequences.
In this study, we employ strategies to enrich for DNA fragments containing HBV sequences from the complex genome of several HCC patients for sequencing using the Next-Generation-GS-FLXSequencer (Roche). Sequencing using the FLX System, which is capable of long read lengths (400-600 bases), rather than other platforms with significantly shorter read lengths, will facilitate the accurate identification of integration sites and the discovery of novel rearrangements within a single read without paired-end sequencing or computational inference providing the confidence that the observed complex structural variations are less probably to be artefactual. Unlike earlier studies, which primarily focused on HBV integration and its 'cis' effects, in this study, we present a systematic characterization of HBV in HCC patients examining both the 'cis' and 'trans' effects of HBV integration as well as structural alterations and HBV sequence variation.
Materials and methods

HCC patient samples
The tumor (T) and adjacent non-tumor (NT) samples of 48 Singaporean HCC patients were used for the HBV enrichment and deep sequencing. All the tissues were from anonymized HCC patients and had prior approval from the National Cancer Centre of Singapore Institutional Review Board (NCC_IRB_ No_2007/437/B). The tissues were obtained from the National Cancer Centre of Singapore Tissue Repository, which had obtained written informed consent from study participants.
Pre-capture DNA library construction Prior to HBV DNA capture, pre-capture DNA library was generated by sonicating 15 µg of genomic DNA to 0.4-1 kb fragments using the Bioruptor® (Diagenode). Genomic DNA extraction was performed as described in Supplementary Materials and Methods (SMM), available at Carcinogenesis Online. The ends of the fragmented DNA were repaired using End-It™ DNA end-repair kit (Epicentre Biotechnologies) to generate blunt-ended fragments. The blunt-ended DNA fragments were then ligated with linkers A (5′-CCATCTCATCCCTGCGTGTCTCCGACTCAG-6mer barcode) and B (5′-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-6mer barcode) (synthesized by AITBiotech). Each set of linkers A and B carry a unique 6mer barcode sequence at the 3′-end of a 30 nucleotide sequence, which serves as priming site for post-HBV capture library amplification. Each of the samples was assigned a set of linkers A and B carrying a unique barcode. Ligation of the linkers allowed pooling of samples for multiplex enrichment and sequencing. The gaps generated by the ligation of non-phosphorylated linkers to the fragments were repaired using the Bst DNA polymerase, large fragment (New England Biolabs). The incorporation of a 6mer barcode unique to each sample will facilitate the identification of each sample in the pool and the correlation of the sequences with clinical phenotypes of the samples (38) .
Design of HBV oligonucleotide probes
Because there are numerous different variants of HBV reported in NCBI GenBank, in order to facilitate the comprehensive enrichment of the different HBV sequences in HCC patients, ~70mer HBV oligonucleotide probes were designed primarily within the conserved regions of 96 different HBV strains that are mainly of genotypes B and C, which represent the most common strains found in Singapore. To ensure exhaustive coverage of the HBV and enrich for all HBV-related sequences whether it is intact or deleted, a total of 26 oligonucleotide probes were designed to span the entire HBV genome at approximately 60 bps apart. As such, some probes have to be designed within the less conserved or polymorphic regions of HBV. These probes were designed such that nucleotide from one genotype (either B or C) was used at every alternate polymorphic site to ensure that the probes can be used to capture HBV of either genotype. When a probe was designed in a highly polymorphic region (>10 polymorphic sites), two haplotypes of oligos were designed to capture both genotypes. All the probes were biotinylated at the 3′-ends.
Enrichment of HBV DNA
To enrich for HBV DNA, the pre-capture DNA library was denatured at 95˚C and hybridized with 10 pmol each the 26 HBV oligonucleotide probes (synthesized by AITBiotech) for 16 h at 55˚C. The hybridization buffer comprised 35% formamide, 5× saline-sodium citrate (SSC), 0.1% sodium dodecyl sulfate (SDS) and 0.1 mM dithiothreitol in a total volume of 350 µl. The probe-bound DNA was then incubated with pre-treated streptavidin-conjugated magnetic beads (Invitrogen) at 55˚C for 30 min. The beads were pre-treated with 1 ml of 4% I-Block buffer (Applied Biosystems) containing 0.5% SDS and 15 ng/µl sonicated salmon sperm DNA (Stratagene) for 50 min at room temperature before use. Non-specific/unbound DNA was removed by five washing steps: step 1: 1× SSC with 0.1% SDS, room temperature, 1 min; step 2: 1× SSC with 0.1% SDS, room temperature, 10 min; steps 3 and 4: 0.1× SSC with 0.1% SDS, 50˚C, 10 min and step 5: H 2 O, room temperature, 30 s. The DNA that remained captured on the beads after these washing steps were eluted by heating at 85˚C for 10 min in H 2 O. The HBV-enriched DNA of 24 patients was then combined and amplified using primers specific to linkers A and B. The primer specific to linker B was 5′-biotinylated. The PCR reactions were carried out using the Advantage 2 PCR Polymerase Mix (Clontech) with the following conditions: 95˚C for 1 min, 95˚C for 40 s, 62˚C for 30 s, 68˚C for 1 min and final extension at 68˚C for 1 min. The PCR products were then concentrated using SpeedVac Plus SC110A (Savant) and run on an agarose gel. Fragments with sizes ranged from 0.4 to 1 kb were extracted and purified using GeneCleanIII kit (MP Biomedicals) according to the manufacturer's instructions. Finally, only single-stranded DNA fragments that were A/B flanked were selected using streptavidin-conjugated magnetic beads (Invitrogen). The enrichment of HBV sequences in human samples will increase the ratio of HBV to background human sequences facilitating the pooling of several patient samples into a single sequencing run making it cost-effective. Quality assessment and sequencing of the HBV DNA-enriched libraries as well as the analysis of sequencing data were performed as described in SMM, available at Carcinogenesis Online.
Evaluation of preferred viral or chromosomal sites for integration and analyses of potential consequences of HBV integrations into the host genome
The statistical significance of the preferred viral, genomic region or chromosomal sites for integration was evaluated by randomly generating integration sites in silico as described in SMM, available at Carcinogenesis Online. Observed integration that is higher than the 99th percentile of the empirical distribution generated from the random sampling will be considered as significant.
The analysis of potential disruption of host gene regulatory element binding sites (REBS) by HBV integration was performed as described in SMM, available at Carcinogenesis Online.
Validation of in silico-inferred contigs from deep sequencing
In silico-inferred contigs were validated through PCR using primers designed at the extreme ends of the contig sequences or immediately before repeat region of the extreme end and subsequent Sanger sequencing as described in SMM, available at Carcinogenesis Online.
Viral-human chimeric transcripts
Expression of viral-human chimeric transcripts was evaluated through reverse transcription-PCR. 5′-and/or 3′-rapid amplification of cDNA ends followed by Sanger sequencing was employed to characterize the entire HBV-human chimeric transcripts. Details are described in SMM, available at Carcinogenesis Online.
Expression and detection of HBx-human chimeric proteins
HBx-human chimeric protein ORFs were predicted using Vector NTI Advance® 10 (Invitrogen). The predicted chimeric protein ORF together with positive [full-length HBx gene from pEco63 (ATCC)] and negative [chloramphenicol acetyltransferase (CAT) gene] controls were cloned and expressed in Huh-7 cells. Western blot analyses with anti-HBx antibody generated in the laboratory (39) was performed to evaluate the expression of the chimeric proteins (see SMM for details, available at Carcinogenesis Online).
Analysis of sequence variation within HBV genome
All contigs or unassembled HBV reads of genotypes B/C were compared with the respective reference sequences to assess the sequence variation of HBV genome in the HCC patients. Variation at the amino acid level of the four major HBV proteins (Polymerase, Large S, Precore/Core and X) was assessed by in silico translation of the DNA sequences (see SMM for details, available at Carcinogenesis Online). 
Results
Greater than 400-fold enrichment of HBV DNA
HBV integrations are predicted to disrupt host gene REBS
A total of 97 integration events were detected in 22 T and 13 NT samples and 46/97 events were randomly chosen for validation.
Characterization of hepatitis B virus using deep sequencing
Supplementary Figure 2 , available at Carcinogenesis Online, shows some of the experimentally validated viral-human contigs/reads.
Although not statistically significant, some enrichment of integration sites was observed in genic regions [defined as the combination of promoters (5 kb upstream of transcription start site; TSS), exons (including 3′-untranslated region; UTR) and introns] in T but not NT samples ( Figure 1A , left). Notably, there was statistically significant enrichment of integration into the promoters of genes (P < 0.001) in T samples ( Figure 1A , right). Integrations in the promoters of 5/7 (71.4%) genes were predicted to disrupt transcription factor binding sites (TFBS) ( Figure 1B) . Notably, in tumors of five patients, HBV integrated into the promoter of TERT gene ( Figure 1B) . Interestingly, the closer the HBV is integrated to the TSS of TERT, the higher was the messenger RNA expression of TERT ( Figure 1B , right), suggesting that viral sequences may act as enhancers (40) . To assess whether HBV integration events are correlated with differential expressions of genes at or in the vicinity of integration sites, we examined the expressions of 58 genes for which expression data are available. These 58 genes are affected by 56 integration events, as two overlapping genes are affected by the same integration events in two cases. As summarized in Supplementary Figure 3 , available at Carcinogenesis Online, 6/8 (75.0%), 2/3 (66.7%) and 14/23 (60.9%) of the integrations in the promoters, exons (including 3′-UTR) and introns, respectively, are associated with differential expressions of the affected genes, whereas only 8/24 (33.3%) of intergenic integrations are associated with differential expression of the genes nearest to the integration sites. Notably, genic (including promoters, exons and introns) integrations are more frequently associated with differential gene expression compared with intergenic integrations (P < 0.05) (Supplementary Figure 3 , available at Carcinogenesis Online) suggesting that one of the mechanisms responsible for differential gene expressions in HCC patients may be related to integration of HBV into genes especially their regulatory regions such as the promoters and introns.
Another noteworthy observation is that HBV integration site at the promoter of KPTN overlaps with the 3′-UTR of the NAPA gene such that HBV integration is predicted to not only disrupt SP1 TFBS of KPTN but also disrupt miR-762 and miR-185* (also known as miR-185-3p) binding sites in the 3′-UTR of NAPA ( Figure 1B) . HBV was found to be integrated into the exons of tumor of only two HCC patients. In one patient, HBV integration into exon 6 of KRT32 gene, which is 448 amino acids long, was predicted to cause premature stop codon ( Figure 1B ) potentially encoding a 403 amino acid truncated KRT32-HBV chimeric protein containing only three amino acids from HBV. HBV integration into exon 37 of 2768 amino acid long TG gene was predicted to potentially encode for a TG-HBV chimeric protein encoding 2167 amino acid from TG and >71 amino acid from reverse complement of HBV.
Greater than 68% of the genic integrations are intronic. Approximately, 25% of the intronic integrations occurred within 400 bps from intron-exon boundaries of annotated genes of which five were predicted to disrupt intronic splicing regulatory element (ISRE) binding sites ( Figure 1B) , suggesting that splicing regulation may be affected. An intronic integration in the tumor of an HCC patient predicted to disrupt an ISRE binding site was observed to reside 383 bps upstream of an alternatively spliced exon (E AS ) in the FAS gene. To test the hypothesis that disruption of ISRE site in tumor will lead to differential expression of E AS in T but not in NT, primers were designed to span and quantitate the E AS (E8 and E9) as well as non-alternative, constitutive exon, E C (E3 and E4). As evident in Figure 1B (right bottom), significant decrease in the amount of E AS compared with E C was observed in T sample (P < 0.05), where HBV integration disrupted the ISRE site, but not in NT sample, where no HBV integration was observed.
HBV preferentially integrates into chromosome 10 in the tumors and integration into chromosome 10 is correlated with poorly differentiated tumors
Circos plots (http://circos.ca/ 1 March 2012, date last accessed) were employed to visualize and analyze the pattern of HBV integrations at the chromosomal level in the T and NT samples. Although relatively random distribution of integration sites was observed in NT, statistically significant enrichment of integration sites on chromosome 10 (P < 0.01, after Bonferroni correction) especially in the q arm was observed in T samples (Figure 2A) . Notably, HBV integration into chromosome 10 was significantly correlated with more poorly differentiated tumors (P < 0.05) ( Figure 2B ). To ensure that this is not a random observation, we also randomly sampled the same number of integration events using the same pool of total integration sites for 1 000 000 times. We then performed Fisher's exact tests to examine the correlation between the randomly selected integration sites and the status of tumor grade. No significant correlation (P > 0.05) was observed between the randomly sampled integration sites and tumor grade in >99% of the random sampling events (data not shown), suggesting that the correlation between integration of HBV into chromosome 10 and poorly differentiated tumors is not a random observation.
Of the 97 HBV integration sites, 14 were found to reside within cancer-related genes of which six were at the promoter of the TERT gene, whereas eight were within introns of oncogene (ERBB4) 
Preferential integration at the 3′-end of HBx and 5′-end of Precore/ Core
Within the HBV genome, statistically significant enrichment of integration events was observed at nucleotides 1600-1900 around the 3′-end of the HBx and 5′-end of the Precore/Core genes in both T (P < 0.001) and NT (P < 0.001) samples (Figures 2A and 3A i ). This region of integration within the HBx gene correlated with lower sequencing reads at the 3′-end of HBx gene as demarcated by the two vertical lines (Figure 3A iii). The increase of coverage at the extreme end of HBx is probably due to the frequent occurrence of integrations at the beginning of Precore/Core (which overlaps with 3′-end of HBx), thereby retaining part of the extreme end of HBx sequences ( Figure 3A ii). When the gross structure of the HBx gene was examined in a different cohort of 49 HCC patients, the 3′-end of HBx was found to be deleted in 49% of T but only 28.6% of NT samples ( Figure 3A iv) , consistent with the observation that higher proportion of integration sites occurring at the 3′ of HBx gene was observed in T (56.1%) compared with NT (42.5%) samples ( Figure 3A i) . Hence, these observations suggest that upon HBV integration, the 3′-end of the HBx gene is often deleted.
Different patterns of structural alterations in HBV genome between the T and NT
Structural alterations within the HBV genome was observed in 39.5% of the HCC patients examined (Supplementary Figures 1C and 4 , available at Carcinogenesis Online, for experimentally validated alterations). As evident from the circos plots ( Figure 3B ), deletion events (green) constitute the majority of the alterations in T (56.1%) and NT (69.4%) samples followed by inversions (red) (38.6% in T and 25% in NT samples), while duplication events (black) were rare.
Interestingly, the 'hotspot' region for HBV integration was also found to be statistically enriched for structural alterations in both NT (P < 0.001) and T (P < 0.001) samples ( Figure 3B ), which could also account for the low sequencing reads in this region and the deletion of the 3′-end of HBx gene as well. Nonetheless, although this 'hotspot' region was enriched in deletion (P < 0.001) and inversion (P < 0.001) events in T, it was only enriched for inversion events (P < 0.001) in NT samples (Supplementary Figure 5 , available at Carcinogenesis Online), suggesting that the pattern of structural alterations in T and NT samples was different.
HBx-human chimeric transcripts are expressed only when integrations occur at the 3′-end of HBx
Among the experimentally validated reads/contigs with HBV-human sequences, chimeric transcripts were observed only when the site of Figure 2 , available at Carcinogenesis Online). Out of the 46 integration events randomly chosen for experimental validation, 18 were located within the HBx gene. Of these 18, human sequences were located upstream of the HBx gene in 2 events and downstream of the HBx gene in 16 events. Of these 16 HBx-human integration events, 14 were experimentally validated to be present at the DNA level and 9 were validated to be expressed as HBx-human chimeric transcripts (Supplementary Table 2 , available at Carcinogenesis Online). Full transcript sequences (2-2.8 kb long) were obtained for three HBxhuman chimeric transcripts using 5′-and 3′-rapid amplification of cDNA ends and ORF prediction revealed the presence of ORFs for HBx-human chimeric protein with intact HBx start codons in all three cases ( Figure 4A ).
The 3′-end of the HBx gene was then further characterized at the transcript level in 23 patients to further evaluate the significance of this 'hotspot' region of integration. Majority of HBx transcripts observed were HBx-human chimeric transcripts (tX-H) (45.5% in T and 55.9% in NT) followed by truncated HBx (tX) (33.3% in T and 23.7% NT), then fulllength (FL) HBx transcripts (18.2% in T and 11.9% in NT) with HBx fused to other HBV sequences (3% in T and 8.5% in NT) being the least abundant ( Figure 4B ). Upon further analyses of the extent of 3′-deletion in the HBx transcripts, we found that the damaged DNA-binding protein 1 (DDB1) binding domain of HBx was rarely deleted ( Figure 4C) . Interestingly, the transactivation domain, but not the p53 binding domain, was conserved in 63.5% and 66.7% of the NT and T transcripts, respectively. These data suggest that in the majority of the patients, altered HBx transcripts encode altered proteins that may affect its binding to the p53 master regulator but retain its ability to transactivate other genes.
HBx-human chimeric proteins can be expressed
Diverse chimeric proteins were predicted from 17 representative chimeric transcripts that were characterized ( Figure 5A ). Within the same patient (e.g. P9, P10, P11 and P12), chimeric ORF predicted in T was different from NT samples. Notably, different variants of HBx-human chimeric protein were predicted to exist even within the same sample (e.g. P12T). Between 3 and 87 amino acid from HBx were deleted, whereas 0-33 amino acid from human sequences were included in the predicted chimeric ORFs ( Figure 5A ).
The chimeric HBx proteins were found to be capable of being expressed in cultured Huh-7 liver cells although their expression was lower than the full-length HBx protein ( Figure 5B ).
Variations in the HBV genome are predicted to cause amino acid substitutions
As the majority of the HBV are of genotypes B and C, sequence variations with respect to these two genotypes were evaluated. As evident in Supplementary Figure 6 , available at Carcinogenesis Online, variability across the entire HBV genome was observed for both genotypes B as well as C and the polymerase and core genes (circled) seemed to be more variable.
Through in silico translation, we examined the potential consequences of these nucleotide variations at the amino acid level for the major HBV proteins, namely, polymerase, large S, Precore/Core and X protein. Overall, there was a significantly higher proportion of nonconservative substitutions compared with conservative substitutions in both NT (P < 0.01) and T (P < 0.05) samples ( Figure 6A ). These preferential non-conservative substitutions were observed only in patients infected with HBV of genotype C (P < 0.05) but not genotype B ( Figure 6B ). Notably, in these patients infected with genotype C, the proportion of non-conservative to conservative substitution was higher in the HBx protein compared with the other three proteins ( Figure 6B ), suggesting that preferential non-conservative substitutions observed in patients with genotype C were primarily contributed by non-conservative substitutions in the HBx gene.
Further examination revealed several variable sites, defined as substitutions occurring in >10% of the samples and potential 'hotspots' defined as substitutions occurring in >20% of the samples (represented in Supplementary Figure 7 , available at Carcinogenesis Online, as downward arrows and boxes, respectively). Different 'variable' and 'hotspot' sites were observed for the two different genotypes examined. The HBx and Precore/Core genes have more variable sites than the other two genes for both genotypes ( Figure 6C ). The X gene also has high proportion of hotspot sites as well. More than intron 7 of FAS gene in the tumor of P37 was predicted to disrupt an ISRE binding site located upstream of an alternatively spliced exon (E AS, exon 8). Significant decrease in the amount of E AS (relative abundance estimated by quantification of boundary of exons 8 and 9) compared with the constitutive exon (E C , relative abundance estimated by quantification of boundary of exons 3 and 4), was observed in the T (P < 0.05), where HBV integration disrupted the ISRE site, but not in NT, where no HBV integration was observed. Primers used for exon quantification were drawn on top of the respective exons. β-actin was used for normalization. Data presented are the mean of three technical replicates. Lengths of introns, exons and UTRs were not drawn to scale. (-), Disruption of ISRE, exonic splicing enhancer (ESE), transcription factor (TF) and microRNA binding sites E, exon. Distances are shown in bps. represented by circos plots. Green, deletions; black, duplications; red, inversions. Regions encompassed by the two ends of the curvy lines represent deleted or duplicated regions. The region spanning nucleotides 1600-1900 of the HBV genome was statistically enriched as sites for structural alterations in both the NT (P < 0.001) and T (P < 0.001) samples, as circled and represented by ***. Figure 7) . These substitutions have the potential to affect the properties or structures of the viral proteins and hence alter their function. The W28Stop (G1896A) 'hotspot' in Precore/Core and I127V/M and K130M in HBx were previously reported to be potential substitution hotspots resulting in a premature stop codon at amino acid 28 of the Precore protein (41) (42) (43) (44) (45) (46) and substitutions of amino acids in HBx protein, respectively (47-53) (Supplementary Figure 7B and A, available at Carcinogenesis Online).
Interestingly, at some hotspot sites, for example, in Large S (S177N and I300T of genotype C) and Polymerase (E16D and S569A of genotypes B and C, respectively) (Supplementary Figure 7C and D) , the amino acids that were substituted were of the other genotype, suggesting either infection with recombinant HBV or co-infection of HBV of both genotypes within the same sample.
Discussion
Although chronic HBV infection had long been associated with significantly higher risk of HCC, its role in hepatocarcinogenesis remains unclear. Due to technological limitations, it was previously challenging to comprehensively characterize HBV in HCC patients. With the recent advent of ultra-high-throughput next generation sequencing (NGS) technology, it is now possible to better characterize HBV in HCC patients. In fact, two of the very recent reports employed paired-end short-reads NGS to characterize HBV integration in HCC patients (36, 37) . Jiang et al. (36) performed very deep whole genome sequencing of only 3 HBV + HCC patients and uncovered 255 HBV integration sites, while Sung et al. (37) also performed whole genome sequencing of 81 HBV + HCC patients and identified 399 integration sites in 75 patients. In this study, we employed enrichment and pooling strategies to enrich for HBV DNA sequences from the complex genome of 48 HCC patients for sequencing using the FLX-Genome-Sequencer. We identified 97 integration events in 26 HCC patients. Although our cost-effective enrichment-pooling strategy identified less integration sites than the other two reports, due to the long read length of the FLX-Genome-Sequencer, all integration sites were identified within the same read without resorting to pairedend sequencing and the exact nucleotides at the integration junction can also be confidently delineated. Notably, with the long reads, we are also able to discover and characterize novel rearrangements in the HBV genome, which has not been characterized in either of the reports. We first examined the potential 'cis' effect of HBV integration. Although the integration of HBV into the human genome superficially seems random, several interesting trends were observed. The first notable observation, which was also reported in the recent NGS characterization of HBV integration (37) , is that in T samples, HBV integrates significantly more frequently into regulatory regions of genes, especially the promoters (P < 0.001), probably due to the relatively more open chromatin configuration in promoter region. One of the most significant observations about HBV integration into promoters of genes is the recurrent integration into the promoter, but not other regions, of the TERT gene in the tumors of five HCC patients, where the expression of the TERT gene correlated with the distance of integration sites from the TSS ( Figure 1B) . Recurrent integration in/ around TERT gene has been frequently reported (19, 37, 54) . Two additional integration sites were found to reside 161 and 364 kb upstream of TERT TSS. These two distant integrations can also potentially affect TERT expression through enhancers within the integrated HBV sequences as was observed in other viral integrations (19, 40, 54) . It is also possible that viral integration could result in the deletion of host sequences adjacent to the integration site (19) , juxtaposing the viral enhancer sequences closer to the host gene to cis-activate the gene. Although the MLL4 gene was also reported to be recurrently targeted by HBV integration (35) (36) (37) 55) , no HBV integration into MLL4 was observed in these HCC patients probably due to differences in patient cohort and characteristics.
Besides the promoter, HBV also integrates into other regulatory regions of genes like introns. For example, HBV integration into the intron of the FAS gene predicted to disrupt an ISRE site was found to disturb the balance between the different isoforms within the cell, which may have different functions under physiological condition. Integration into introns might also influence the expression of genes involved as some introns might contain enhancer elements or alternative promoters that regulate gene expression (56) .
The second significant observation is that the profile of integration in NT is different from that of T samples. In the tumors, HBV preferentially integrates into chromosome 10, suggesting that while integration of HBV into the host genome may be random, only a few integration events can alter cellular homeostasis and promote tumorigenesis and hence are selected during tumorigenesis. In fact, HBV integration into chromosome 10 was found to be significantly associated with more poorly differentiated tumors highlighting the clinical relevance of chromosome 10 integration. Some of the integrations in chromosome 10 occurred within cancer-associated genes (e.g. FAS and MSMB) suggesting that deregulation of these genes might increase the aggressiveness of the tumors. This observation is consistent with previous studies reporting that chromosome 10 showed high instability in poorly or moderately differentiated HCC in rat (57) . It is noteworthy that majority of the integration in chromosome 10 occurred in the q arm (10q), where loss of heterozygosity was reported to be a frequent event in a subset of HCC (57-59), suggesting the presence of genes involved in the progression or development of HCC in that arm of the chromosome.
We also characterized the HBV genome in HCC patients, which may influence tumorigenesis in 'trans.' The preferential site within the HBV genome that integrates into the human genome was found to reside around the cohesive end region spanning nucleotides 1600-1900 of HBV, which is the site of initiation of viral replication and transcription (60) . Similar preferential HBV integration region was also reported in previous studies characterizing HBV integration using NGS (36, 37) . This study also found that the same region was also statistically enriched as sites for viral genome deletions in tumor and inversions in T and NT samples, strongly suggesting that the mechanism of viral integrations into host cellular DNA or other viral structural alterations might occur via intermediates of replication or transcription (60) .
It is important to also note that only when the site of integration is at the 3′-end of HBx was chimeric transcripts observed. These chimeric transcripts often carry deletions at the 3′-end of HBx resulting in C-terminal truncated HBx protein, which was reported to modulate microRNA expression (61) , regulate Wnt-5a expression (62), abrogate the growth-suppressive and apoptotic effects of full-length HBx (63) (64) (65) as well as enhance cellular proliferation in vitro (64, 66) and tumorigenicity in vivo (67, 68) . Although the extent of deletion of the 3′-end of HBx gene varies, majority of the deletion did not affect the DDB1 binding domain, suggesting that the DDB1 binding domain is often conserved probably to prevent the HBx protein from being rapidly degraded because HBx was reported to be protected from proteasome-mediated degradation when it interacts with DDB1 (69). Because the 3′-end of HBx overlaps with the core promoter region in the HBV genome, the dominance of these HBx C-terminal deleted mutants could also be due to the selection of cells producing reduced or no core antigen (HBcAg) as the HBcAg was reported as a viral target antigen for the host immune response (70) . These observations suggest that although complex alterations of HBV can be found at the DNA level, only a subset of these complex alterations that provide selective advantage are expressed.
In addition to complex structural alterations and integration events deleting the 3′-end of the HBx gene and generating HBx-human chimeric transcripts leading to chimeric proteins observed in the HBV genome in HCC patients, great variability within HBV genome sequence was also observed. Notably, significantly more non-conservative substitutions especially with respect to genotype C and in the HBx gene were observed. These non-conservative substitutions may change the property/structure of the protein perhaps influencing its tumorigenic potential or facilitating their evasion from the host immune surveillance. As there are overlaps between different ORFs of the HBV proteins, variation in the DNA sequence may lead to amino acid changes in more than one viral protein. Hence, there may also be co-selection of some variants through pressure exerted on another protein.
In summary, our data suggest that HBV preferentially integrates into promoters of genes and chromosome 10 in tumor of HCC patients. Notably, integration into chromosome 10 is associated with higher grade or more poorly differentiated tumors. Upon integration, the 3′-end of the HBx gene is often deleted and HBx-human chimeric transcripts, which can be expressed as chimeric proteins, are most commonly observed. The HBV genome within HCC patients shows great sequence variation especially non-conservative substitutions and structural alterations, particularly, deletions and inversions but rarely duplications.
In conclusion, this study suggests that HBV may contribute to HCC through one or more mechanisms. Integration of HBV into the host genome has the primary 'cis' effect of altering regulation of genes. Sequence variations and structural alterations of HBV genome modifying the viral proteins' structure/function and integration events generating novel HBx-human chimeric proteins may exert 'trans' effect by facilitating the evasion of host immune surveillance and/or contributing to tumorigenesis.
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